Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesCorrelation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis
Journal of Rheumatology, 06/16/09
Odai T et al. – Data suggest that the CX3CL1-CX3CR1 system in patients with active rheumatoid arthritis (RA) may be sensitive to anti-tumor necrosis factor-α therapy, and confirm that CX3CL1 plays a crucial role in the pathogenesis of RA.
Methods- Aim was to examine:
- Relation between serum chemokine levels and patient responsiveness to infliximab, and
- Influence of infliximab administration on serum chemokine levels
- Serum levels of the chemokines CX3CL1, CXCL8, CCL3, and CXCL10 were quantified at baseline and after 30 wks of treatment with infliximab in 20 pts using ELISA
- Disease status was assessed using DAS28
- Response to infliximab was classified according to EULAR response criteria
- By 30 wks, infliximab produced a overall reduction in DAS28 in all pts, although only 12 achieved a good to moderate response based on EULAR response criteria
- A reduction in CX3CL1 was seen in the responsive group; infliximab treatment had no effect on other 3 chemokines
- DAS28, ESR, CRP, and CX3CL1 levels were all diminished by infliximab in RA pts with lower basal CX3CL1 levels, but not in those with higher basal levels
- Cell-surface expression of CX3CR1 protein in peripheral blood CD8+CD3+ T cells and mRNA expression of CX3CR1 in lymphocytes were both downregulated after infliximab treatment in the responsive group
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Sponsor
Article Search
Sponsor